Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: January 27, 2012
Last updated: February 17, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2014
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 17, 2016